文章研究表明，表观药物Panobinostat和Tazemetostat的组合可以通过对肿瘤细胞的组蛋白修饰重编程，抑制与肿瘤进展相关的基因表达。通过HiTIP-seq技术，研究人员对来自DMG患者肿瘤干细胞的表观修饰改变进行了深入分析，揭示了这两种 ...

Malignant gliomas and medulloblastomas also exhibit heterogeneity at the cellular level, with subpopulations of tumour cells harbouring stem-like properties rendering them more resistant to therapy.

《Acta Neuropathologica Communications》：Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells ...

A progress report for a phase 1 trial of CLD-101 in recurrent glioma shows safety and feasibility at multiple intracerebral ...

Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, ...

A key problem is the ability of glioma stem cells to regenerate tumors after treatment and resist conventional therapies, making them a primary reason for treatment failure. Recent discoveries ...

DelveInsight’s, “Glioma Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline ...

Stem cell-like glioma cancer cells that share many characteristics with normal stem cells propel the lethal growth of brain cancers by promoting tumor blood vessel formation. Stem cell-like glioma ...

Glioblastoma multiforme (GBM), commonly referred to as glioblastoma, is a malignant intracranial tumor derived from glial ...

Glioblastoma, one of the most aggressive and lethal brain cancers, has a five-year survival rate of only 6.9%, according to the National Brain Tumor Society. While the relationship between ...